Ai-Driven Discovery Of Celecoxib And Dexamethasone For :@0.104762:0.111208:0.834737:0.111208:0.834737:0.083261:0.104762:0.083261:0.020619:0.007939:0.009510:0.020619:0.012680:0.007939:0.014279:0.012680:0.015878:0.007140:0.020619:0.007939:0.011109:0.012680:0.014279:0.014279:0.012680:0.012680:0.014279:0.007140:0.022218:0.009510:0.007140:0.020619:0.012680:0.007939:0.012680:0.012680:0.014279:0.014279:0.007939:0.015878:0.005532:0.020619:0.015878:0.015878:0.007140:0.020619:0.012680:0.014279:0.014279:0.023789:0.012680:0.009510:0.015878:0.014279:0.011109:0.014279:0.015878:0.012680:0.007140:0.017449:0.014279:0.012174:0.007140
Exploring Their Mode Of Action As Human Interleukin:@0.104762:0.137337:0.785209:0.137337:0.785209:0.109391:0.104762:0.109391:0.019048:0.014279:0.015878:0.007939:0.014279:0.012680:0.007939:0.015878:0.014279:0.006617:0.019048:0.015878:0.012680:0.007939:0.012157:0.007140:0.026959:0.014279:0.015878:0.012680:0.007140:0.022218:0.009510:0.005555:0.020619:0.012680:0.009510:0.007939:0.014279:0.015878:0.005563:0.020619:0.011109:0.007140:0.022218:0.015878:0.023789:0.014279:0.015878:0.007140:0.011109:0.015878:0.009510:0.012680:0.012680:0.007939:0.012680:0.015878:0.015878:0.007939:0.015878
(Il-6) Inhibitors To Treat Covid-19-Induced Cytokine Storm In :@0.104762:0.163466:0.875916:0.163466:0.875916:0.135520:0.104762:0.135520:0.009510:0.011109:0.007939:0.009510:0.014279:0.009510:0.007140:0.011109:0.015878:0.015878:0.007939:0.015878:0.007939:0.009510:0.014279:0.012680:0.011109:0.006631:0.016427:0.014279:0.006625:0.016926:0.012160:0.012680:0.014279:0.009510:0.007140:0.020619:0.014279:0.014279:0.007939:0.015878:0.009510:0.014279:0.014279:0.009510:0.011109:0.015878:0.015878:0.015878:0.012680:0.012680:0.015878:0.007140:0.020619:0.014279:0.009510:0.014279:0.015878:0.007939:0.015878:0.012680:0.007140:0.015878:0.009510:0.014279:0.012680:0.023789:0.007140:0.011109:0.015878:0.007140
Humans:@0.104762:0.189596:0.207914:0.189596:0.207914:0.161649:0.104762:0.161649:0.022218:0.015878:0.023789:0.014279:0.015878:0.011109
Current Pharmaceutical Design. 2023 Oct; 29(34): 2752 – 2762.:@0.188385:0.214217:0.811626:0.214217:0.811626:0.191950:0.188385:0.191950:0.015687:0.013076:0.009149:0.009149:0.010442:0.013076:0.006538:0.005880:0.014370:0.013076:0.011759:0.009149:0.018297:0.011759:0.010442:0.010442:0.013076:0.006538:0.006538:0.010442:0.011759:0.006538:0.005880:0.016980:0.010442:0.009149:0.006538:0.011759:0.013076:0.005880:0.005880:0.011759:0.011759:0.011759:0.011759:0.005880:0.016980:0.010442:0.006538:0.007832:0.005880:0.011759:0.011759:0.007832:0.011759:0.011759:0.007832:0.007832:0.005880:0.011759:0.011759:0.011759:0.011759:0.005880:0.011759:0.005880:0.011759:0.011759:0.011759:0.011759:0.005880
------------------------------------------------------------------------------------:@0.171052:0.240341:0.828912:0.240341:0.828912:0.217942:0.171052:0.217942:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832
Israa M. Shamkh , Mahmoud Elkazzaz, Enas. S. Radwan, Jawayria Najeeb, Md. :@0.114500:0.266407:0.891253:0.266407:0.891253:0.244459:0.114500:0.244459:0.009018:0.009018:0.009018:0.011591:0.011591:0.005796:0.020609:0.005796:0.005796:0.012889:0.012889:0.011591:0.018036:0.011591:0.012889:0.005796:0.005796:0.005796:0.020609:0.011591:0.012889:0.018036:0.011591:0.012889:0.011591:0.005796:0.015463:0.006445:0.011591:0.011591:0.009018:0.009018:0.011591:0.009018:0.005796:0.005796:0.015463:0.012889:0.011591:0.009018:0.005796:0.005796:0.012889:0.005796:0.005796:0.015463:0.011591:0.011591:0.015463:0.011591:0.012889:0.005796:0.005796:0.011591:0.011591:0.015463:0.011591:0.010293:0.009018:0.006445:0.011591:0.005796:0.016738:0.011591:0.006445:0.010293:0.010293:0.011591:0.005796:0.005796:0.020609:0.011591:0.005796:0.005796
Tabish Rehman , Mohamed F. Alajmi, Moayad Shahwan, Muhammad Sufyan, :@0.124260:0.292535:0.881540:0.292535:0.881540:0.270587:0.124260:0.270587:0.012034:0.011591:0.011591:0.006445:0.009018:0.012889:0.005796:0.015463:0.010293:0.012889:0.018036:0.011591:0.012889:0.005796:0.005796:0.005796:0.020609:0.011591:0.012889:0.011591:0.018036:0.010293:0.011591:0.005796:0.012475:0.005796:0.004933:0.015463:0.006445:0.011591:0.006445:0.018036:0.006445:0.005796:0.005796:0.020609:0.011591:0.011591:0.010293:0.011591:0.011591:0.005796:0.012889:0.012889:0.011591:0.012889:0.015463:0.011591:0.012889:0.005796:0.005796:0.020609:0.012889:0.012889:0.011591:0.018036:0.018036:0.011591:0.011591:0.005796:0.012889:0.012889:0.007720:0.010293:0.011591:0.012889:0.005796:0.005796
Nouf Khalifa Alaqeel, Ibrahim A. Ibrahim, Basit Jabbar, Mohammad Shahbaz :@0.123749:0.318664:0.882066:0.318664:0.882066:0.296715:0.123749:0.296715:0.016738:0.011591:0.012889:0.007720:0.005796:0.015463:0.012889:0.011591:0.006445:0.006445:0.007720:0.011591:0.004936:0.015463:0.006445:0.011591:0.011591:0.010293:0.010293:0.006445:0.005796:0.005796:0.009018:0.011591:0.009018:0.011591:0.012889:0.006445:0.018036:0.004936:0.015463:0.005796:0.005796:0.009018:0.011591:0.009018:0.011591:0.012889:0.006445:0.018036:0.005796:0.005796:0.015463:0.011591:0.009018:0.006445:0.006445:0.005796:0.011591:0.011591:0.011591:0.011591:0.011591:0.007741:0.005796:0.005796:0.020609:0.011591:0.012889:0.011591:0.018036:0.018036:0.011591:0.011591:0.005796:0.012889:0.012889:0.011591:0.012889:0.011591:0.011591:0.009018:0.005796
Khan, Tomasz M. Karpiński, Abdullah Haikal, Reem M. Aljowaie, Saeedah :@0.140928:0.344792:0.864890:0.344792:0.864890:0.322844:0.140928:0.322844:0.015463:0.012889:0.011591:0.012889:0.005796:0.005796:0.012032:0.011591:0.018036:0.011591:0.009018:0.009018:0.005796:0.020609:0.005796:0.005796:0.015463:0.011591:0.009018:0.011591:0.006445:0.012889:0.009018:0.011591:0.006445:0.005796:0.004936:0.015463:0.011591:0.011591:0.012889:0.006445:0.006445:0.011591:0.012889:0.005796:0.018036:0.011591:0.006445:0.011591:0.011591:0.006445:0.005796:0.005796:0.015463:0.010293:0.010293:0.018036:0.005796:0.020609:0.005796:0.004936:0.015463:0.006445:0.006445:0.011591:0.015463:0.011591:0.006445:0.010293:0.005796:0.005796:0.012889:0.011591:0.010293:0.010293:0.011591:0.011591:0.012889:0.005796
Musaed Almutairi,  Amr Ahmed:@0.347020:0.370920:0.652983:0.370920:0.652983:0.348972:0.347020:0.348972:0.020609:0.012889:0.009018:0.011591:0.010293:0.011591:0.004938:0.015463:0.006445:0.018036:0.012889:0.006445:0.011591:0.006445:0.009018:0.006445:0.005796:0.005796:0.004938:0.015463:0.018036:0.009018:0.004938:0.015463:0.012889:0.018036:0.010293:0.011591
Faculty of Pharmacy Newsletter:@0.147970:0.965677:0.401979:0.965677:0.401979:0.947594:0.147970:0.947594:0.011291:0.009239:0.008205:0.010274:0.005137:0.006153:0.009239:0.004620:0.009239:0.006153:0.004620:0.011291:0.010274:0.009239:0.008205:0.015393:0.009239:0.008205:0.009239:0.004620:0.013342:0.008205:0.013342:0.007188:0.005137:0.008205:0.006153:0.006153:0.008205:0.008205
Reference::@0.104524:0.810980:0.210310:0.810980:0.210310:0.788714:0.104524:0.788714:0.015687:0.010442:0.007832:0.010442:0.009149:0.010442:0.013076:0.010442:0.010442:0.007832
https://doi.org/10.2174/0113816128260449231017091824:@0.104524:0.830509:0.497446:0.830509:0.497446:0.814509:0.104524:0.814509:0.008399:0.004670:0.004670:0.008399:0.006535:0.004670:0.004670:0.004670:0.008399:0.008399:0.004670:0.004200:0.008399:0.005277:0.008399:0.004670:0.008399:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.004670:0.008399:0.007771:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399
Abstract:@0.104762:0.390669:0.213026:0.390669:0.213026:0.362722:0.104762:0.362722:0.020905:0.016164:0.011395:0.009795:0.012965:0.014565:0.012965:0.009510
Background::@0.104762:0.412560:0.219542:0.412560:0.219542:0.392833:0.104762:0.392833:0.013647:0.010281:0.009152:0.011410:0.010281:0.008785:0.010281:0.011410:0.011410:0.011410:0.006713
 In the case of COVID-19 patients, it has been observed that the immune system :@0.219743:0.412260:0.900219:0.412260:0.900219:0.393061:0.219743:0.393061:0.006108:0.006914:0.010281:0.006108:0.005806:0.010281:0.009152:0.006108:0.009152:0.009152:0.008043:0.009152:0.006108:0.010281:0.006914:0.006108:0.013647:0.014756:0.014756:0.006914:0.014756:0.006914:0.010281:0.010281:0.006108:0.010281:0.009152:0.005806:0.005806:0.009152:0.010281:0.005806:0.008043:0.005241:0.006108:0.005806:0.005806:0.006108:0.010281:0.009152:0.008043:0.006108:0.010281:0.009152:0.009152:0.010281:0.006108:0.010281:0.010281:0.008043:0.009152:0.006914:0.010281:0.009152:0.010281:0.006108:0.005806:0.010281:0.009152:0.005806:0.006108:0.005806:0.010281:0.009152:0.006108:0.005806:0.015885:0.015885:0.010281:0.010281:0.009152:0.006108:0.008043:0.010281:0.008043:0.005806:0.009152:0.015681:0.005040
of the infected person exhibits an extreme inflammatory response known as cytokine release :@0.104762:0.429365:0.900303:0.429365:0.900303:0.410165:0.104762:0.410165:0.010281:0.006914:0.007479:0.005806:0.010281:0.009152:0.007479:0.005806:0.010281:0.006914:0.009152:0.009152:0.005806:0.009152:0.010281:0.007479:0.010281:0.009152:0.006914:0.008043:0.010281:0.010281:0.007479:0.009152:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.008043:0.007479:0.009152:0.010281:0.007479:0.009152:0.010281:0.005806:0.006914:0.009152:0.015885:0.009152:0.007479:0.005806:0.010281:0.006914:0.005806:0.009152:0.015885:0.015885:0.009152:0.005806:0.010281:0.006914:0.010281:0.007479:0.006914:0.009152:0.008043:0.010281:0.010281:0.010281:0.008043:0.009152:0.007479:0.010281:0.010281:0.010281:0.014756:0.010281:0.007479:0.009152:0.008043:0.007479:0.009152:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.009152:0.007479:0.006914:0.009152:0.005806:0.009152:0.009152:0.008043:0.008948:0.005040
syndrome (CRS) where the inflammatory cytokines are swiftly produced in quite large amounts :@0.104762:0.446469:0.900461:0.446469:0.900461:0.427269:0.104762:0.427269:0.008043:0.010281:0.010281:0.010281:0.006914:0.010281:0.015885:0.009152:0.005261:0.006914:0.013647:0.013647:0.011410:0.006914:0.005261:0.014756:0.010281:0.009152:0.006914:0.009152:0.005261:0.005806:0.010281:0.009152:0.005261:0.005806:0.010281:0.006914:0.005806:0.009152:0.015885:0.015885:0.009152:0.005806:0.010281:0.006914:0.010281:0.005261:0.009152:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.009152:0.008043:0.005261:0.009152:0.006914:0.009152:0.005261:0.008043:0.014756:0.005806:0.006914:0.005806:0.005806:0.010281:0.005261:0.010281:0.006914:0.010281:0.010281:0.010281:0.009152:0.009152:0.010281:0.005261:0.005806:0.010281:0.005261:0.010281:0.010281:0.005806:0.005806:0.009152:0.005251:0.005806:0.009152:0.006552:0.010281:0.009152:0.005261:0.009152:0.015885:0.010281:0.010281:0.010281:0.005806:0.007846:0.005040
in response  to  infective stimuli. Numerous case studies of COVID-19 patients  with  severe :@0.104762:0.463573:0.900404:0.463573:0.900404:0.444374:0.104762:0.444374:0.005806:0.010281:0.009152:0.006914:0.009152:0.008043:0.010281:0.010281:0.010281:0.008043:0.009152:0.005040:0.004102:0.005806:0.010281:0.005040:0.004102:0.005806:0.010281:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.009152:0.008043:0.005806:0.005806:0.015885:0.010281:0.005806:0.005806:0.005241:0.009152:0.014756:0.010281:0.015885:0.009152:0.006914:0.010281:0.010281:0.008043:0.009152:0.009152:0.009152:0.008043:0.009152:0.009152:0.008043:0.005806:0.010281:0.010281:0.005806:0.009152:0.008043:0.009152:0.010281:0.006914:0.009152:0.013647:0.014756:0.014756:0.006914:0.014756:0.006914:0.010281:0.010281:0.009152:0.010281:0.009152:0.005806:0.005806:0.009152:0.010281:0.005806:0.008043:0.005040:0.004102:0.014756:0.005806:0.005806:0.010281:0.005040:0.004102:0.008043:0.009152:0.010281:0.009152:0.006914:0.008948:0.005040
symptoms have documented the presence of higher plasma concentrations of human interleukin-6 :@0.104762:0.480678:0.900366:0.480678:0.900366:0.461478:0.104762:0.461478:0.008043:0.010281:0.015885:0.010281:0.005806:0.010281:0.015885:0.008043:0.003729:0.010281:0.009152:0.010281:0.009152:0.003729:0.010281:0.010281:0.009152:0.010281:0.015885:0.009152:0.010281:0.005806:0.009152:0.010281:0.003729:0.005806:0.010281:0.009152:0.003729:0.010281:0.006914:0.009152:0.008043:0.009152:0.010281:0.009152:0.009152:0.003729:0.010281:0.006914:0.003729:0.010281:0.005806:0.010281:0.010281:0.009152:0.006914:0.003729:0.010281:0.005806:0.009152:0.008043:0.015885:0.009152:0.003729:0.009152:0.010281:0.010281:0.009152:0.009152:0.010281:0.005806:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.003729:0.010281:0.006914:0.003729:0.010281:0.010281:0.015885:0.009152:0.010281:0.003729:0.005806:0.010281:0.005806:0.009152:0.006914:0.005806:0.009152:0.010281:0.010281:0.005806:0.010281:0.006914:0.010079:0.005040
(IL-6), which suggests that IL-6 is a crucial factor in the pathophysiology of the disease. In order :@0.104762:0.497782:0.900346:0.497782:0.900346:0.478582:0.104762:0.478582:0.006914:0.006914:0.012519:0.006914:0.010281:0.006914:0.005241:0.004556:0.014756:0.010281:0.005806:0.009152:0.010281:0.004556:0.008043:0.010281:0.010281:0.010281:0.009152:0.008043:0.005806:0.008043:0.004556:0.005806:0.010281:0.009152:0.005806:0.004556:0.006914:0.012519:0.006914:0.010281:0.004556:0.005806:0.008043:0.004556:0.009152:0.004556:0.009152:0.006914:0.010281:0.009152:0.005806:0.009152:0.005806:0.004556:0.006914:0.009152:0.009152:0.005806:0.010281:0.006914:0.004556:0.005806:0.010281:0.004556:0.005806:0.010281:0.009152:0.004556:0.010281:0.009152:0.005806:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.005806:0.010281:0.005806:0.010281:0.010281:0.010281:0.004556:0.010281:0.006914:0.004556:0.005806:0.010281:0.009152:0.004556:0.010281:0.005806:0.008043:0.009152:0.009152:0.008043:0.009152:0.005241:0.004556:0.006914:0.010281:0.004556:0.010281:0.006914:0.010281:0.009152:0.006713:0.005040
to prevent CRS in COVID-19 patients, the drugs that can exhibit binding interactions with IL-6 :@0.104762:0.514887:0.900426:0.514887:0.900426:0.495687:0.104762:0.495687:0.005806:0.010281:0.005382:0.010281:0.006914:0.009152:0.010281:0.009152:0.010281:0.005806:0.005382:0.013647:0.013647:0.011410:0.005382:0.005806:0.010281:0.005382:0.013647:0.014756:0.014756:0.006914:0.014756:0.006914:0.010281:0.010281:0.005382:0.010281:0.009152:0.005806:0.005806:0.009152:0.010281:0.005806:0.008043:0.005241:0.005382:0.005806:0.010281:0.009152:0.005382:0.010281:0.006914:0.010281:0.010281:0.008043:0.005382:0.005806:0.010281:0.009152:0.005806:0.005382:0.009152:0.009152:0.010281:0.005382:0.009152:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.005382:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.005382:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.005382:0.014756:0.005806:0.005806:0.010281:0.005382:0.006914:0.012519:0.006914:0.010079:0.005040
and block the signaling pathways to decrease the IL-6 activity may be repurposed. :@0.104762:0.531991:0.797335:0.531991:0.797335:0.512791:0.104762:0.512791:0.009152:0.010281:0.010281:0.005907:0.010281:0.005806:0.010281:0.009152:0.010281:0.005907:0.005806:0.010281:0.009152:0.005907:0.008043:0.005806:0.010281:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.005907:0.010281:0.009152:0.005806:0.010281:0.014756:0.009152:0.010281:0.008043:0.005907:0.005806:0.010281:0.005907:0.010281:0.009152:0.009152:0.006914:0.009152:0.009152:0.008043:0.009152:0.005907:0.005806:0.010281:0.009152:0.005907:0.006914:0.012519:0.006914:0.010281:0.005907:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.010281:0.005907:0.015885:0.009152:0.010281:0.005907:0.010281:0.009152:0.005907:0.006914:0.009152:0.010281:0.010281:0.006914:0.010281:0.010281:0.008043:0.009152:0.010281:0.005040:0.005040
Methods::@0.104762:0.556122:0.187917:0.556122:0.187917:0.536395:0.104762:0.536395:0.019231:0.009152:0.006914:0.011410:0.010281:0.011410:0.008043:0.006713
  This research work focused on molecular docking-based screening of the drugs :@0.188118:0.555823:0.900366:0.555823:0.900366:0.536623:0.188118:0.536623:0.005040:0.004189:0.012519:0.010281:0.005806:0.008043:0.009596:0.006914:0.009152:0.008043:0.009152:0.009152:0.006914:0.009152:0.010281:0.009596:0.014756:0.010281:0.006914:0.010281:0.009596:0.006914:0.010281:0.009152:0.010281:0.008043:0.009152:0.010281:0.009596:0.010281:0.010281:0.009596:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.009596:0.010281:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.006914:0.010281:0.009152:0.008043:0.009152:0.010281:0.009596:0.008043:0.009152:0.006914:0.009152:0.009152:0.010281:0.005806:0.010281:0.010281:0.009596:0.010281:0.006914:0.009596:0.005806:0.010281:0.009152:0.009596:0.010281:0.006914:0.010281:0.010281:0.007846:0.005040
celecoxib (CXB) and dexamethasone (DME) to explore their potential to interact with the :@0.104762:0.572927:0.900463:0.572927:0.900463:0.553728:0.104762:0.553728:0.009152:0.009152:0.005806:0.009152:0.009152:0.010281:0.010281:0.005806:0.010281:0.009313:0.006914:0.013647:0.014756:0.013647:0.006914:0.009313:0.009152:0.010281:0.010281:0.009313:0.010281:0.009152:0.010281:0.009152:0.015885:0.009152:0.005806:0.010281:0.009152:0.008043:0.010281:0.010281:0.009152:0.009313:0.006914:0.014756:0.018123:0.012519:0.006914:0.009313:0.005806:0.010281:0.009313:0.009152:0.010281:0.010281:0.005806:0.010281:0.006914:0.009152:0.009313:0.005806:0.010281:0.009152:0.005806:0.006914:0.009313:0.010281:0.010281:0.005806:0.009152:0.010281:0.005806:0.005806:0.009152:0.005806:0.009313:0.005806:0.010281:0.009313:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.009313:0.014756:0.005806:0.005806:0.010281:0.009313:0.005806:0.010281:0.008946:0.005040
binding sites of IL-6 protein and reduce the hyper-activation of IL-6 in the infected personnel.:@0.104762:0.590032:0.895367:0.590032:0.895367:0.570832:0.104762:0.570832:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.006189:0.008043:0.005806:0.005806:0.009152:0.008043:0.006189:0.010281:0.006914:0.006189:0.006914:0.012519:0.006914:0.010281:0.006189:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.006189:0.009152:0.010281:0.010281:0.006189:0.006914:0.009152:0.010281:0.010281:0.009152:0.009152:0.006189:0.005806:0.010281:0.009152:0.006189:0.010281:0.010281:0.010281:0.009152:0.006511:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.006189:0.010281:0.006914:0.006189:0.006914:0.012519:0.006914:0.010281:0.006189:0.005806:0.010281:0.006189:0.005806:0.010281:0.009152:0.006189:0.005806:0.010281:0.006914:0.009152:0.009152:0.005806:0.009152:0.010281:0.006189:0.010281:0.009152:0.006914:0.008043:0.010281:0.010281:0.010281:0.009152:0.005806:0.005040
Results::@0.104762:0.614163:0.175600:0.614163:0.175600:0.594436:0.104762:0.594436:0.014756:0.009152:0.008043:0.011410:0.005806:0.006914:0.008043:0.006713
 Both of the drugs were observed to bind with the IL-6 (IL-6 receptor alpha chain) and :@0.175801:0.613864:0.900366:0.613864:0.900366:0.594664:0.175801:0.594664:0.005544:0.013647:0.010281:0.005806:0.010281:0.005544:0.010281:0.006914:0.005544:0.005806:0.010281:0.009152:0.005544:0.010281:0.006914:0.010281:0.010281:0.008043:0.005544:0.014756:0.009152:0.006914:0.009152:0.005544:0.010281:0.010281:0.008043:0.009152:0.006914:0.010281:0.009152:0.010281:0.005544:0.005806:0.010281:0.005544:0.010281:0.005806:0.010281:0.010281:0.005544:0.014756:0.005806:0.005806:0.010281:0.005544:0.005806:0.010281:0.009152:0.005544:0.006914:0.012519:0.006914:0.010281:0.005544:0.006914:0.006914:0.012519:0.006914:0.010281:0.005544:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.005544:0.009152:0.005806:0.010281:0.010281:0.009152:0.005544:0.009152:0.010281:0.009152:0.005806:0.010281:0.006914:0.005544:0.009152:0.010281:0.010079:0.005040
IL-6Rα receptor with the respective affinities of -7.3 kcal/mol and -6.3 kcal/mol, respectively, :@0.104762:0.630968:0.900400:0.630968:0.900400:0.611769:0.104762:0.611769:0.006914:0.012519:0.006914:0.010281:0.013647:0.010765:0.006457:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.006457:0.014756:0.005806:0.005806:0.010281:0.006457:0.005806:0.010281:0.009152:0.006457:0.006914:0.009152:0.008043:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.006457:0.009152:0.006552:0.006914:0.005806:0.010281:0.005806:0.005806:0.005806:0.009152:0.008043:0.006459:0.010281:0.006914:0.006457:0.006914:0.010281:0.005241:0.010281:0.006457:0.010281:0.009152:0.009152:0.005806:0.005806:0.015885:0.010281:0.005806:0.006457:0.009152:0.010281:0.010281:0.006457:0.006914:0.010281:0.005241:0.010281:0.006457:0.010281:0.009152:0.009152:0.005806:0.005806:0.015885:0.010281:0.005806:0.005241:0.006457:0.006914:0.009152:0.008043:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.008971:0.005040:0.005040
for CXB and DME. Moreover, various types of binding interactions of the drugs with the target :@0.104762:0.648073:0.900263:0.648073:0.900263:0.628873:0.104762:0.628873:0.006914:0.010281:0.006914:0.005382:0.013647:0.014756:0.013647:0.005382:0.009152:0.010281:0.010281:0.005382:0.014756:0.018123:0.012519:0.005241:0.005382:0.018123:0.010281:0.006914:0.009152:0.010281:0.010281:0.009152:0.006108:0.005241:0.005382:0.010281:0.009152:0.006914:0.005806:0.010281:0.010281:0.008043:0.005382:0.005806:0.010281:0.010281:0.009152:0.008043:0.005382:0.010281:0.006914:0.005382:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.005382:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.005382:0.010281:0.006914:0.005382:0.005806:0.010281:0.009152:0.005382:0.010281:0.006914:0.010281:0.010281:0.008043:0.005382:0.014756:0.005806:0.005806:0.010281:0.005382:0.005806:0.010281:0.009152:0.005382:0.005806:0.009152:0.006552:0.010281:0.009152:0.005602:0.005040
proteins were also observed in the docking studies. The dynamic behaviors of IL-6/IL-6Rα in :@0.104762:0.665177:0.900354:0.665177:0.900354:0.645977:0.104762:0.645977:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.008043:0.006681:0.014756:0.009152:0.006914:0.009152:0.006681:0.009152:0.005806:0.008043:0.010281:0.006679:0.010281:0.010281:0.008043:0.009152:0.006914:0.010281:0.009152:0.010281:0.006679:0.005806:0.010281:0.006679:0.005806:0.010281:0.009152:0.006681:0.010281:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.006679:0.008043:0.005806:0.010281:0.010281:0.005806:0.009152:0.008043:0.005241:0.006316:0.012519:0.010281:0.009152:0.006679:0.010281:0.010281:0.010281:0.009152:0.015885:0.005806:0.009152:0.006681:0.010281:0.009152:0.010281:0.009152:0.010281:0.005806:0.010281:0.006914:0.008043:0.006679:0.010281:0.006914:0.006679:0.006914:0.012519:0.006914:0.010281:0.005806:0.006914:0.012519:0.006914:0.010281:0.013647:0.010765:0.006681:0.005806:0.010079:0.005040
complex with the drugs were also explored through molecular dynamics simulation analysis. :@0.104762:0.682281:0.900406:0.682281:0.900406:0.663082:0.104762:0.663082:0.009152:0.010281:0.015885:0.010281:0.005806:0.009152:0.010281:0.007499:0.014756:0.005806:0.005806:0.010281:0.007499:0.005806:0.010281:0.009152:0.007499:0.010281:0.006914:0.010281:0.010281:0.008043:0.007499:0.014756:0.009152:0.006914:0.009152:0.007499:0.009152:0.005806:0.008043:0.010281:0.007499:0.009152:0.010281:0.010281:0.005806:0.010281:0.006914:0.009152:0.010281:0.007499:0.005806:0.010281:0.006914:0.010281:0.010281:0.010281:0.010281:0.007499:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.007499:0.010281:0.010281:0.010281:0.009152:0.015885:0.005806:0.009152:0.008043:0.007499:0.008043:0.005806:0.015885:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.007499:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.008043:0.005040:0.005040
The results indicated significant stabilities of the acquired drug-protein complexes up to 100 ns.:@0.104762:0.699386:0.895407:0.699386:0.895407:0.680186:0.104762:0.680186:0.012519:0.010281:0.009152:0.005120:0.006914:0.009152:0.008043:0.010281:0.005806:0.005806:0.008043:0.005120:0.005806:0.010281:0.010281:0.005806:0.009152:0.009152:0.005806:0.009152:0.010281:0.005120:0.008043:0.005806:0.010281:0.010281:0.005806:0.006914:0.005806:0.009152:0.009152:0.010281:0.005806:0.005120:0.008043:0.005806:0.009152:0.010281:0.005806:0.005806:0.005806:0.005806:0.005806:0.009152:0.008043:0.005120:0.010281:0.006914:0.005120:0.005806:0.010281:0.009152:0.005120:0.009152:0.009152:0.010281:0.010281:0.005806:0.006914:0.009152:0.010281:0.005120:0.010281:0.006914:0.010281:0.010281:0.006914:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.005120:0.009152:0.010281:0.015885:0.010281:0.005806:0.009152:0.010281:0.009152:0.008043:0.005120:0.010281:0.010281:0.005120:0.005806:0.010281:0.005120:0.010281:0.010281:0.010281:0.005120:0.010281:0.008043:0.005040
Conclusion::@0.104762:0.723517:0.209829:0.723517:0.209829:0.703790:0.104762:0.703790:0.014756:0.010281:0.011410:0.009152:0.005806:0.011410:0.008043:0.005806:0.010281:0.011410:0.006713
 The findings of this study have suggested the potential of the drugs studied to be :@0.210031:0.723218:0.900301:0.723218:0.900301:0.704018:0.210031:0.704018:0.005846:0.012519:0.010281:0.009152:0.006209:0.006914:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.008043:0.006209:0.010281:0.006914:0.006209:0.005806:0.010281:0.005806:0.008043:0.006209:0.008043:0.005806:0.010281:0.010281:0.010281:0.006209:0.010281:0.009152:0.010281:0.009152:0.006209:0.008043:0.010281:0.010281:0.010281:0.009152:0.008043:0.005806:0.009152:0.010281:0.006209:0.005806:0.010281:0.009152:0.006209:0.010281:0.010281:0.005806:0.009152:0.010281:0.005806:0.005806:0.009152:0.005806:0.006209:0.010281:0.006914:0.006209:0.005806:0.010281:0.009152:0.006209:0.010281:0.006914:0.010281:0.010281:0.008043:0.006209:0.008043:0.005806:0.010281:0.010281:0.005806:0.009152:0.010281:0.006209:0.005806:0.010281:0.006209:0.010281:0.008946:0.005040
utilized as antagonists for countering CRS in COVID-19 ailment. This study presents the studied :@0.104762:0.740322:0.900364:0.740322:0.900364:0.721122:0.104762:0.721122:0.010281:0.005806:0.005806:0.005806:0.005806:0.009152:0.009152:0.010281:0.004495:0.009152:0.008043:0.004495:0.009152:0.010281:0.005806:0.009152:0.010281:0.010281:0.010281:0.005806:0.008043:0.005806:0.008043:0.004495:0.006914:0.010281:0.006914:0.004495:0.009152:0.010281:0.010281:0.010281:0.005806:0.009152:0.006914:0.005806:0.010281:0.010281:0.004495:0.013647:0.013647:0.011410:0.004495:0.005806:0.010281:0.004495:0.013647:0.014756:0.014756:0.006914:0.014756:0.006914:0.010281:0.010281:0.004495:0.009152:0.005806:0.005806:0.015885:0.009152:0.010281:0.005806:0.005241:0.004131:0.012519:0.010281:0.005806:0.008043:0.004495:0.008043:0.005806:0.010281:0.010281:0.010281:0.004495:0.010281:0.006914:0.009152:0.008043:0.009152:0.010281:0.005806:0.008043:0.004495:0.005806:0.010281:0.009152:0.004495:0.008043:0.005806:0.010281:0.010281:0.005806:0.009152:0.010079:0.005040
drugs as promising candidates both for the clinical and pre-clinical treatment of COVID-19.:@0.104762:0.757427:0.867144:0.757427:0.867144:0.738227:0.104762:0.738227:0.010281:0.006914:0.010281:0.010281:0.008043:0.005443:0.009152:0.008043:0.005443:0.010281:0.006914:0.010281:0.015885:0.005806:0.008043:0.005806:0.010281:0.010281:0.005443:0.009152:0.009152:0.010281:0.010281:0.005806:0.010281:0.009152:0.005806:0.009152:0.008043:0.005443:0.010281:0.010281:0.005806:0.010281:0.005443:0.006914:0.010281:0.006914:0.005443:0.005806:0.010281:0.009152:0.005443:0.009152:0.005806:0.005806:0.010281:0.005806:0.009152:0.009152:0.005806:0.005443:0.009152:0.010281:0.010281:0.005443:0.010281:0.006914:0.009152:0.006914:0.009152:0.005806:0.005806:0.010281:0.005806:0.009152:0.009152:0.005806:0.005443:0.005806:0.006914:0.009152:0.009152:0.005806:0.015885:0.009152:0.010281:0.005806:0.005443:0.010281:0.006914:0.005443:0.013647:0.014756:0.014756:0.006914:0.014756:0.006914:0.010281:0.010281:0.005040
104:@0.090000:0.971012:0.136899:0.971012:0.136899:0.940075:0.090000:0.940075:0.015180:0.015180:0.016540
Chapter V:@0.103809:0.063855:0.209433:0.063855:0.209433:0.040840:0.103809:0.040840:0.016980:0.013076:0.011759:0.013076:0.007832:0.010442:0.010021:0.005456:0.016980